HONG KONG, March 10, 2026 /PRNewswire/ — Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a global leader in in advanced brain health diagnostics. The partnership will introduce the PrecivityAD2™ blood test to healthcare professionals across Hong Kong, enabling access to C2N's innovative technology that aids in the diagnosis of Alzheimer's disease.The PrecivityAD2™ test is intended for individuals aged 50 years and older with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. The PrecivityAD2™ test detects the presence or…